Cardiff Oncology, Inc. (CRDF) stock
CRDFNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$0.84−0.01 (-0.87%)
Close on Nov 18, 2026Market cap $65.27MP/E –Yield –
Cardiff Oncology ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Cardiff Oncology's ebitda for the twelve months ending Jun 30, 2026 was -$41.92M. For fiscal 2025 it was -$48.60M. The highest annual figure on record is -$2.97M in fiscal 2011.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$48.60M | – |
| FY2024 | Dec 31, 2024 | -$48.25M | – |
| FY2023 | Dec 31, 2023 | -$45.01M | – |
| FY2022 | Dec 31, 2022 | -$39.67M | – |
| FY2021 | Dec 31, 2021 | -$28.40M | – |
| FY2020 | Dec 31, 2020 | -$18.62M | – |
| FY2019 | Dec 31, 2019 | -$16.18M | – |
| FY2018 | Dec 31, 2018 | -$16.19M | – |
| FY2017 | Dec 31, 2017 | -$24.35M | – |
| FY2016 | Dec 31, 2016 | -$39.08M | – |
| FY2015 | Dec 31, 2015 | -$24.89M | – |
| FY2014 | Dec 31, 2014 | -$14.71M | – |
| FY2013 | Dec 31, 2013 | -$10.56M | – |
| FY2012 | Dec 31, 2012 | -$4.81M | – |
| FY2011 | Dec 31, 2011 | -$2.97M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$9.53M | – |
| Q1 FY2026 | Mar 31, 2026 | -$12.76M | – |
| Q4 FY2025 | Dec 31, 2025 | -$7.74M | – |
| Q3 FY2025 | Sep 30, 2025 | -$11.89M | – |
| Q2 FY2025 | Jun 30, 2025 | -$14.68M | – |
| Q1 FY2025 | Mar 31, 2025 | -$14.29M | – |
| Q4 FY2024 | Dec 31, 2024 | -$12.48M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.50M | – |
| Q2 FY2024 | Jun 30, 2024 | -$12.44M | – |
| Q1 FY2024 | Mar 31, 2024 | -$10.83M | – |
| Q4 FY2023 | Dec 31, 2023 | -$10.23M | – |
| Q3 FY2023 | Sep 30, 2023 | -$10.71M | – |
| Q2 FY2023 | Jun 30, 2023 | -$12.11M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.96M | – |
| Q4 FY2022 | Dec 31, 2022 | -$9.31M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.91M | – |
| Q2 FY2022 | Jun 30, 2022 | -$10.41M | – |
| Q1 FY2022 | Mar 31, 2022 | -$11.04M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.41M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.89M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.78M | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.32M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.38M | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.25M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.99M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.01M | – |
| Q4 FY2019 | Dec 31, 2019 | -$4.17M | – |
| Q3 FY2019 | Sep 30, 2019 | -$4.08M | – |
| Q2 FY2019 | Jun 30, 2019 | -$4.10M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.83M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.95M | – |
| Q3 FY2018 | Sep 30, 2018 | -$3.64M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.21M | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.40M | – |
| Q4 FY2017 | Dec 31, 2017 | -$3.49M | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.49M | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.57M | – |
| Q1 FY2017 | Mar 31, 2017 | -$9.79M | – |
| Q4 FY2016 | Dec 31, 2016 | -$9.41M | – |
| Q3 FY2016 | Sep 30, 2016 | -$9.72M | – |
See a number that looks wrong?